Goldline Pharmaceutical Limited, a Nagpur-based pharmaceutical marketing company incorporated in 2004, is set to launch its initial public offering (IPO) on May 12, 2026. The SME issue is a pure fresh issue of ₹8.35 crore with no offer for sale (OFS) component, and the IPO will close on May 14, 2026. The company markets pharmaceutical products under its proprietary 'Goldline' brand across five distinct segments, operating entirely on an asset-light, third-party contract manufacturing model with 15 contract manufacturers and 8 distributors.

IPO Structure and Key Dates

The offering details as disclosed in the Draft Red Herring Prospectus (DRHP) are summarised below.

The net proceeds from the issue are intended for repayment of outstanding borrowings — including unsecured loans, term loans, and working capital facilities — with a portion allocated to general corporate purposes capped at the lower of 15% of gross proceeds or ₹1,000.00 lakhs.

Company Profile and Business Model

Goldline Pharmaceutical does not own or operate any manufacturing facility. Instead, it relies on 15 third-party contract manufacturers who produce products based on the company's market research, demand analysis, and specifications, with manufacturer lead times ranging from 15 to 60 days. Products are distributed through 8 distributors, with credit terms of 60 days extended to distributors. The company's geographic focus is concentrated in Maharashtra and Madhya Pradesh, which together account for over 70% of revenue.

The company markets products across five branded segments:

• Goldline Pharma — Core pharmaceutical products
• Goldline Cardinal — Specialty pharmaceutical range
• Goldline Aayushman — Healthcare-focused products
• Goldline InLife — Lifestyle and wellness products
• Goldline Wellness — General wellness products

Three promoter group entities — Numerius Healthcare, Nucleage Lifescience, and Nucleage Pharma Solutions — are engaged in similar pharmaceutical businesses and collectively contributed 22.04% of the company's revenue as distributors, indicating significant related-party dependency alongside potential conflicts of interest.

Financial Performance

The company has reported consistent revenue growth over the reviewed periods. Revenue from operations grew from ₹19.85 crore in FY2023 to ₹23.57 crore in FY2024 and further to ₹28.06 crore in FY2025. For the nine months ended December 31, 2025 (Q3 FY2026), revenue stood at ₹21.41 crore.

Profitability improved significantly over the period, with PAT margin expanding from 1.31% in FY2023 to 10.09% in FY2025. Total equity grew from ₹5.89 crore in FY2023 to ₹12.36 crore as of Q3 FY2026, while the debt-to-equity ratio declined from 2.29x to 1.22x over the same period. The current ratio improved from 1.87x in FY2023 to 2.24x in Q3 FY2026. Operating cash flows remained consistently positive across all periods reviewed.

Balance Sheet and Cash Flow Overview

The company's balance sheet reflects steady asset growth and an improving equity position. The detailed breakdown of assets and liabilities across reviewed periods is presented below.

Total borrowings stood at ₹913.78 lakhs as of March 31, 2026. Trade receivables increased from ₹862.74 lakhs in FY2023 to ₹1,290.45 lakhs as of Q3 FY2026, reflecting the company's 60-day credit terms extended to distributors. Investing cash flow turned positive in FY2025 at ₹0.16 crore, suggesting possible asset disposals or reduced capital expenditure.

Key Financial Ratios

The table below summarises key profitability, efficiency, and leverage ratios across the reviewed periods.

Return on equity improved substantially from 4.41% in FY2023 to 27.34% in FY2025, driven by the dramatic expansion in net profitability. Declining leverage — with the debt-to-equity ratio falling from 2.29x to 1.54x — reflects consistent debt repayment, a trend the IPO proceeds are intended to accelerate. The current ratio above 1.9x indicates adequate short-term liquidity across all reviewed periods.

Key Risk Factors

Investors should note the following material risks disclosed in the DRHP:

• Third-party manufacturer dependence: The company relies entirely on 15 contract manufacturers with lead times of 15–60 days, with no manufacturing backup.
• Concentrated distribution: Only 8 distributors handle a significant portion of revenue, creating high counterparty concentration risk.
• Related-party revenue dependency: Promoter group entities contributed 22.04% of revenue as distributors, alongside potential conflicts of interest given their engagement in similar businesses.
• Geographic concentration: Maharashtra and Madhya Pradesh account for over 70% of revenue.
• Outstanding litigation: Exposure includes ₹271.23 lakhs in direct tax matters, ₹63.70 lakhs in indirect tax matters, and ₹7.75 lakhs in regulatory actions.
• Total borrowings: ₹913.78 lakhs as of March 31, 2026, with promoters as co-borrowers on unsecured loans totalling ₹1.67 crore.
• Unrecognised MSME interest: Outstanding balances of ₹81.35 lakhs as of December 31, 2025, with an estimated interest liability of approximately ₹1.10 lakhs not yet provisioned.
• Regulatory compliance lapses: Late fees totalling over ₹1.5 lakhs for ROC filing delays and late fees of ₹25,000+ for GST payment delays.
• IPO proceeds allocation: The primary use of IPO proceeds is debt repayment rather than business expansion or capacity building.

Management Team

The promoters and key management personnel collectively bring more than 5 decades of combined industry experience in pharmaceutical marketing, distribution, and business development. The leadership team comprises the following individuals:

Investment Perspective

Goldline Pharmaceutical presents a growth-stage pharmaceutical marketing company with improving financial metrics but significant concentration risks. The asset-light model, consistent revenue growth of approximately 19% per annum, and improving ROE of 27.34% in FY2025 are key positives. The primary use of IPO proceeds towards debt reduction is expected to improve interest coverage and reduce financial leverage further. However, the small scale of operations at ₹28.06 crore revenue, complete manufacturing dependency on third parties, concentrated distribution through only 8 distributors, geographic concentration in two states, and promoter-group conflicts of interest are material concerns that investors must weigh carefully.

The price band, lot size, and reservation category details have not been disclosed in the DRHP data available. Investors are advised to refer to the complete DRHP and consult their financial advisors before making any investment decisions.